The CSF biomarker profile defining AD consists of a low CSF Aβ1–42 or Aβ1–42/Aβ1-40 ratio, elevated CSF p-Tau and elevated CSF t-Tau [177,178]. Here, MAPT is linked to Alzheimer disease.